Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:EDIT NASDAQ:MIRM NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.33-0.2%$3.45$1.72▼$8.21$565.88M2.085.29 million shs452,778 shsEDITEditas Medicine$2.73-2.0%$2.95$1.66▼$4.54$265.83M2.12.07 million shs518,917 shsMIRMMirum Pharmaceuticals$112.17-2.0%$108.49$50.25▼$130.00$6.83B0.48900,093 shs683,609 shsSRPTSarepta Therapeutics$15.88+0.4%$17.23$10.41▼$25.32$1.68B0.213.08 million shs616,407 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-2.63%-9.51%+9.54%-25.17%+39.33%EDITEditas Medicine-3.81%-8.55%-0.71%-13.40%-17.26%MIRMMirum Pharmaceuticals-2.20%-5.39%+6.23%+24.50%+119.35%SRPTSarepta Therapeutics-2.41%-10.16%-10.37%-22.53%+16.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.33-0.2%$3.45$1.72▼$8.21$565.88M2.085.29 million shs452,778 shsEDITEditas Medicine$2.73-2.0%$2.95$1.66▼$4.54$265.83M2.12.07 million shs518,917 shsMIRMMirum Pharmaceuticals$112.17-2.0%$108.49$50.25▼$130.00$6.83B0.48900,093 shs683,609 shsSRPTSarepta Therapeutics$15.88+0.4%$17.23$10.41▼$25.32$1.68B0.213.08 million shs616,407 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-2.63%-9.51%+9.54%-25.17%+39.33%EDITEditas Medicine-3.81%-8.55%-0.71%-13.40%-17.26%MIRMMirum Pharmaceuticals-2.20%-5.39%+6.23%+24.50%+119.35%SRPTSarepta Therapeutics-2.41%-10.16%-10.37%-22.53%+16.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 3.00Buy$12.10263.36% UpsideEDITEditas Medicine 2.57Moderate Buy$5.4094.24% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$143.4025.26% UpsideSRPTSarepta Therapeutics 2.08Hold$23.9051.10% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, CTMX, EDIT, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026CTMXCytomX Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/20/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)7/17/2026EDITEditas Medicine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/9/2026SRPTSarepta Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$23.00 ➝ $20.007/9/2026SRPTSarepta Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$27.007/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$142.00 ➝ $148.007/7/2026SRPTSarepta Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/2/2026MIRMMirum Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$115.00 ➝ $125.006/29/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)6/23/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/16/2026CTMXCytomX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 7/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$76.20M7.44N/AN/A$0.58 per share5.74EDITEditas Medicine$40.52M6.72N/AN/A$0.28 per share9.93MIRMMirum Pharmaceuticals$521.31M13.39$0.05 per share2,296.04$6.12 per share18.71SRPTSarepta Therapeutics$2.18B0.76N/AN/A$10.89 per share1.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)EDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%8/11/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A880.62N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A8.110.18-2.94%7.56%2.94%8/5/2026 (Estimated)Latest SRPT, CTMX, EDIT, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026EDITEditas Medicine-$0.30N/AN/AN/A$2.85 millionN/A8/6/2026Q2 2026CTMXCytomX Therapeutics-$0.11N/AN/AN/A$12.39 millionN/A8/5/2026Q2 2026SRPTSarepta Therapeutics$0.4861N/AN/AN/A$381.98 millionN/A7/30/2026Q2 2026MIRMMirum Pharmaceuticals-$0.7279N/AN/AN/A$166.03 millionN/A5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A10.3810.38EDITEditas MedicineN/A3.223.22MIRMMirum Pharmaceuticals1.282.091.99SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%EDITEditas Medicine71.90%MIRMMirum PharmaceuticalsN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics3.80%EDITEditas Medicine3.10%MIRMMirum Pharmaceuticals8.32%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170170.19 million163.72 millionOptionableEDITEditas Medicine23097.91 million94.87 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableSRPT, CTMX, EDIT, and MIRM HeadlinesRecent News About These CompaniesSarepta Therapeutics to Announce Second Quarter 2026 Financial ResultsJuly 22 at 11:26 AM | finance.yahoo.comSRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?July 22 at 11:26 AM | finance.yahoo.comSRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?July 22 at 10:26 AM | zacks.comSarepta Therapeutics to Announce Second Quarter 2026 Financial ResultsJuly 22 at 9:00 AM | businesswire.comSRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne SpaceJuly 21 at 5:38 PM | stocktwits.comSSarepta Therapeutics Stock Short Interest Rises to 32.62%July 21 at 9:31 AM | quiverquant.comQSarepta Skids After A Rival Clears A Key Hurdle In The Duchenne SpaceJuly 20 at 2:58 PM | finance.yahoo.comuniQure Trends to Watch as Gene Therapy Bets Shift Beyond HemgenixJuly 17, 2026 | finance.yahoo.comFollowing FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued?July 14, 2026 | finance.yahoo.comThe Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD TherapiesJuly 13, 2026 | finance.yahoo.comJohnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)July 13, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)July 11, 2026 | theglobeandmail.comSarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.July 10, 2026 | businesswire.comIonis Pharmaceuticals Drops Another 9% as Bad News Piles UpJuly 10, 2026 | 247wallst.comModerna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech RoutJuly 10, 2026 | 247wallst.comModerna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech RoutJuly 10, 2026 | 247wallst.comSarepta Therapeutics (NASDAQ:SRPT) Shares Down 6.3% After Analyst DowngradeJuly 10, 2026 | marketbeat.comThis Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally NextJuly 9, 2026 | finance.yahoo.comSarepta Therapeutics (NASDAQ:SRPT) Given New $20.00 Price Target at Piper SandlerJuly 9, 2026 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Upgraded by Wolfe Research to Outperform RatingJuly 9, 2026 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Lowered to Strong Sell Rating by Zacks ResearchJuly 9, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally HereBy Jeffrey Neal Johnson | June 26, 2026Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred SharesBy Jeffrey Neal Johnson | July 5, 2026Oracle Is One Step From Junk—Can It Afford the AI Boom?By Sam Quirke | July 21, 2026Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesBy Chris Markoch | July 21, 2026SRPT, CTMX, EDIT, and MIRM Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$3.32 -0.01 (-0.15%) As of 11:58 AM Eastern This is a fair market value price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$2.72 -0.06 (-1.98%) As of 11:57 AM Eastern This is a fair market value price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$112.16 -2.32 (-2.02%) As of 11:58 AM Eastern This is a fair market value price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Sarepta Therapeutics NASDAQ:SRPT$15.88 +0.06 (+0.37%) As of 11:58 AM Eastern This is a fair market value price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Philip Morris Trimmed Guidance, But Its Growth Story Looks Unshaken The 2026 Blueprint: 6 Stocks for a Brand New Portfolio Cementing the Sky: Why NVIDIA’s Bet on Nebius Matters Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Rocket Lab Has Corrected Nearly 50%. Is It Still Too Expensive? Cybersecurity ETFs Are Rallying While AI Stocks Cool Off Thematic Memory ETFs Give Investors a New Way to Play AI’s Hidden Bottleneck Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
